Amphastar Pharmaceuticals (AMPH) Set to Announce Quarterly Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.95 per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. On average, analysts expect Amphastar Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Amphastar Pharmaceuticals Stock Performance

AMPH stock traded down $0.37 on Wednesday, reaching $50.78. The company's stock had a trading volume of 289,249 shares, compared to its average volume of 393,458. The firm has a fifty day moving average of $48.09 and a two-hundred day moving average of $43.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. The company has a market capitalization of $2.48 billion, a P/E ratio of 17.80, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. Amphastar Pharmaceuticals has a 52 week low of $36.56 and a 52 week high of $65.92.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, October 18th. Finally, Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Insider Buying and Selling

In other news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company's stock, valued at $3,504,256.23. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the firm's stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares in the company, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard K. Prins sold 17,101 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the transaction, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,101 shares of company stock worth $1,069,350. 27.10% of the stock is owned by insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.